Is a 6-Week Course of Ganciclovir Therapy Effective for Chorioretinitis in Infants with Congenital Cytomegalovirus Infection?

Received 7 October 2009; received in revised form 29 December 2009; accepted 16 February 2010. published online 19 April 2010.

Refers to article:

Congenital Cytomegalovirus Infection: Screening and Treatment , 14 June 2010
Robert F. Pass
The Journal of Pediatrics
August 2010 (Vol. 157, Issue 2, Pages 179-180)
Full Text | Full-Text PDF (104 KB)

Use of Screening Dried Blood Spots for Estimation of Prevalence, Risk Factors, and Birth Outcomes of Congenital Cytomegalovirus Infection , 19 April 2010
Martin Kharrazi, Terri Hyde, Suzanne Young, Minal M. Amin, Michael J. Cannon, Sheila C. Dollard
The Journal of Pediatrics
August 2010 (Vol. 157, Issue 2, Pages 191-197)
Abstract | Full Text | Full-Text PDF (208 KB)

Effective treatment for chorioretinitis caused by congenital cytomegalovirus (CMV) infection remains unknown. We report an infant with congenital CMV infection, who required a 6-month course of antiviral therapy to control his chorioretinitis. Long-term treatment may be necessary for managing congenital CMV-associated chorioretinitis.

CMV, Cytomegalovirus, GCV, Ganciclovir, Ig, Immunoglobulin, Val-GCV, Valganciclovir

a Division of General Pediatrics, Department of Interdisciplinary Medicine, National Center for Child Health and Development, Tokyo, Japan

b Division of Neonatology, Department of Maternal and Perinatal Services, National Center for Child Health and Development, Tokyo, Japan

c Department of Virology I, National Institute of Infectious Disease, Tokyo, Japan

d Division of Ophthalmology, Department of Surgical Subspecialties, National Center for Child Health and Development, Tokyo, Japan

e Division of Infectious Disease, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan

Reprint requests: Akihiko Saitoh, MD, PhD, FAAP, 2-10-1 Okura, Setagaya-ku, Tokyo 157-0074 Japan.

Supported by a grant from the Ministry of Health and Welfare (H20-Kodomo-007 to Y.I. and N.Inoue). The authors declare no conflicts of interest.

PII: S0022-3476(10)00144-7

doi:10.1016/j.jpeds.2010.02.020

44 of 55